Syntekabio Signs Memorandum of Understanding with bioSeedin/ACROBiosystems
20 juin 2024 10h00 HE
|
Syntekabio USA Inc.
DAEJEON, South Korea, June 20, 2024 (GLOBE NEWSWIRE) -- Syntekabio (KOSDAQ: 226330), an artificial intelligence (AI) based drug development company, announced the signing of a strategic Memorandum...
Syntekabio to Showcase Advanced AI Drug Discovery Technologies at BIO International Convention 2024
23 mai 2024 10h00 HE
|
Syntekabio USA Inc.
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Syntekabio (226330.KQ), a global artificial intelligence (AI) drug discovery pioneer, today announced its participation at the BIO International Convention...
Syntekabio to Showcase Biologics Discovery Platform at PEGS Boston
07 mai 2024 10h30 HE
|
Syntekabio USA Inc.
NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Syntekabio (226330.KQ), a global artificial intelligence (AI) drug discovery pioneer, today announced its participation at the 20th Annual PEGS Boston –...
Syntekabio to Showcase Innovative AI Drug Discovery Technologies at Bio-IT World
11 avr. 2024 10h15 HE
|
Syntekabio USA Inc.
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Syntekabio (226330.KQ), a global artificial intelligence (AI) drug discovery pioneer, today announced its participation at the upcoming Bio-IT World...
Syntekabio (KOSDAQ:226330.KQ) Presents Neoantigen Prediction Technology at Cancer Immunotherapy Conference CICON22
26 sept. 2022 15h07 HE
|
Syntekabio
New York, N.Y., United States, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Syntekabio (KOSDAQ:226330.KQ), a global AI drug discovery and development company, will present its neoantigen prediction technology...